Shares of Shield Therapeutics plc (LON:STX – Get Free Report) were down 8.2% during mid-day trading on Thursday . The company traded as low as GBX 3.30 ($0.04) and last traded at GBX 3.35 ($0.04). Approximately 2,331,377 shares were traded during trading, a decline of 53% from the average daily volume of 4,971,186 shares. The stock had previously closed at GBX 3.65 ($0.05).
Shield Therapeutics Price Performance
The company has a current ratio of 2.28, a quick ratio of 2.16 and a debt-to-equity ratio of 134.67. The stock has a market capitalization of £26.59 million, a P/E ratio of -88.50 and a beta of 1.27. The stock has a 50 day moving average of GBX 2.33 and a 200-day moving average of GBX 2.42.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Flowers Foods’ Q2 Earnings: Is Now the Right Time to Invest?
- What is the S&P/TSX Index?
- Top 3 Michael Burry Stock Picks to Watch in 2024
- How to Calculate Stock Profit
- Target Hits the Mark: Q2 Earnings Exceed Expectations
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
